Citalopram relieves depression in head and neck cancer patients
22 May 2008

Scientists have suggested that prescribing head and neck cancer patients with citalopram can help to prevent them from becoming depressed.

A study published in the Archives of Otolaryngology - Head & Neck Surgery shows that those receiving therapy for their condition are more likely to be in a good mood state if given a course of the antidepressant.

Researchers studied 36 patients as part of the investigation to determine whether citalopram hydrobromide could stunt major depressive disorder in patients undergoing cancer therapy.

The subjects were randomly selected to take either 40mg of citalopram hydrobromide or a placebo for 12 weeks.

In the group taking the placebo, two members became suicidal compared to no patients in the citalopram group.

Using the Hamilton Depression Rating Scale, the researchers found that the mood state of 15 per cent of the group taking the antidepressants was rated as at least mildly ill – compared to 60 per cent in the placebo group.

Further, the quality of life of those taking part - rated by the University of Washington Quality of Life scale - worsened in both groups, but more so for those taking the placebo drug.

"Psychiatric morbidity in these patients is frequent and underdiagnosed," said the report.

"Major depressive disorder has been reported in up to 40 per cent of patients with head and neck cancer, typically within the first three months of diagnosis."

It added that the study "suggests a tangible means to improve outcome in patients with head and neck cancer and supports additional research toward this aim".

Register now to access our FREE educational library

Print Article    Bookmark

• Study highlights lack of sleep and exercise as cancer risk 18/11/08
• Doctors warned over pre-eclampsia risk in pregnant women 05/11/08
• Yoghurt found to reduce cancer risk 17/10/08
• Gender link explored in CHD research 14/10/08
• Additional testing may improve breast cancer risk assessment 29/07/08

• TRITACE Tablets - 24.72%
  ... more who have one or more of the following clinical findings: hypertension (systolic blood pressure> 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease ...
  
  
• TRITACE Titration Pack - 24.36%
  ... who have one or more of the following clinical findings: hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease. Oral ...
  
  
• BETAFERON - 23.54%
  ... of clinical relapses in ambulatory patients, who have had at least two attacks of neurological dysfunction in the preceding two years followed by complete or incomplete recovery. Secondary progressive multiple sclerosis - Slowing progression of disease and reduction in frequency of clinical relapses ...
  
  
• LOCOID Ointment - 22.5%
  The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided ...
  
  
• NAGLAZYME Solution for Infusion - 22.5%
  ... it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease. A key issue is to treat young patients aged <5 years suffering from a severe form of the disease, even though patients <5 ...
  
  
• ELAPRASE Solution for Infusion - 22.5%
  Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials ...